Ultragenyx Q1 revenue $100.5M (+26% YoY); net loss $164M; reaffirms FY 2023 guidance

Ultragenyx Pharmaceutical Inc.

2023-Q1 EPS reported -$2.33 revenue$100,496,000

Crysvita revenue $76M (+28% YoY), Dojolvi $14.3M (+15%), Mepsevii $8.5M.
Net loss per share $2.33 vs $2.19 in Q1 2022; op ex $254.6M incl $31.9M stock comp.
Cash & equivalents $714.6M; reaffirms FY 2023 total revenue $425-450M, net cash used <$400M.
UX143 OI Phase 2 complete, data & Phase 3 initiation expected mid-2023.
GTX-102 expansion cohorts dosing; next data update in 2H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ultragenyx Pharmaceutical Inc. reported First Quarter 2023 results: revenue $ 100,496, net income $ (163,972 ), EPS $ (2.33 ). Guidance reaffirmed.

Period: First Quarter 2023
Revenue: $ 100,496
Net income: $ (163,972 )
EPS: $ (2.33 )
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Selected Financial Data (dollars in thousands, except per share amounts), (unaudited) Three Months Ended March 31, 2023 2022 Total revenues $ 100,496 $ 79,935 Operating expense: Cost of sales 12,257 6,100 Research and development 165,698 143,155 Selling, general and administrative 76,646 67,312 Total operating expense 254,601 216,567 Net loss $ (163,972 ) $ (152,320 ) Net loss per share, basic and diluted $ (2.33 ) $ (2.19 )

View on SEC.gov

Browse all earnings releases →

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-017852

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.